Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 145

1.

DSM-5 in patients seeking their first treatment for alcohol use disorder. Sex differences in the multicenter CohRTA study.

Sanvisens A, Zuluaga P, Rubio G, Short A, Gual A, Álvarez FJ, Torrens M, Rodríguez de Fonseca F, Muga Bustamante R, Estudio CohRTA EC.

Adicciones. 2019 Apr 8;0(0):1177. doi: 10.20882/adicciones.1177. [Epub ahead of print] English, Spanish.

2.

The relationship between motivations for cannabis consumption and problematic use.

Casajuana Kögel C, López-Pelayo H, Oliveras C, Colom J, Gual A, Balcells-Oliveró MM.

Adicciones. 2019 Apr 8;0(0):1221. doi: 10.20882/adicciones.1221. [Epub ahead of print] English, Spanish.

3.

The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial.

Barrio P, Roncero C, Ortega L, Guardia J, Yuguero L, Gual A.

J Clin Med. 2019 Apr 6;8(4). pii: E471. doi: 10.3390/jcm8040471.

4.

The High-Risk Alcoholism Relapse Score Predicts Alcohol Relapse Among Liver Transplant Candidates with Less Than Six Months of Abstinence.

Lombardo-Quezada J, Colmenero J, López-Pelayo H, Gavotti C, Lopez A, Crespo G, Lopez E, Gual A, Lligoña A, Navasa M.

Liver Transpl. 2019 Mar 28. doi: 10.1002/lt.25460. [Epub ahead of print]

PMID:
30920118
5.

Why Less Is Always More in the Treatment of Alcohol Use Disorders.

Nutt DJ, Gual A, Anderson P, Rehm J.

JAMA Psychiatry. 2019 Mar 13. doi: 10.1001/jamapsychiatry.2018.2807. [Epub ahead of print] No abstract available.

PMID:
30865234
6.

Cerebellar alterations in cannabis users: A systematic review.

Blithikioti C, Miquel L, Batalla A, Rubio B, Maffei G, Herreros I, Gual A, Verschure P, Balcells-Oliveró M.

Addict Biol. 2019 Feb 27. doi: 10.1111/adb.12714. [Epub ahead of print]

PMID:
30811097
7.

Identifying Triggers of Alcohol Craving to Develop Effective Virtual Environments for Cue Exposure Therapy.

Ghiţă A, Teixidor L, Monras M, Ortega L, Mondon S, Gual A, Paredes SM, Villares Urgell L, Porras-García B, Ferrer-García M, Gutiérrez-Maldonado J.

Front Psychol. 2019 Jan 29;10:74. doi: 10.3389/fpsyg.2019.00074. eCollection 2019.

8.

Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse.

López-Pelayo H, Miquel L, Altamirano J, Bataller R, Caballeria J, Ortega L, Lligoña A, Gual A.

J Psychosom Res. 2019 Jan;116:75-82. doi: 10.1016/j.jpsychores.2018.11.020. Epub 2018 Nov 28.

PMID:
30654998
9.

Risky Alcohol Use: The Impact on Health Service Use.

Miquel L, Manthey J, Rehm J, Vela E, Bustins M, Segura L, Vieta E, Colom J, Anderson P, Gual A.

Eur Addict Res. 2018;24(5):234-244. doi: 10.1159/000493884. Epub 2018 Oct 3.

PMID:
30282079
10.

New Alcohol Biomarkers. New challenges.

Barrio P, Wurst FM, Gual A.

Alcohol Alcohol. 2018 Nov 1;53(6):762-763. doi: 10.1093/alcalc/agy064. No abstract available.

PMID:
30204846
11.

Publisher Correction: Alcoholic liver disease.

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.

Nat Rev Dis Primers. 2018 Aug 28;4(1):18. doi: 10.1038/s41572-018-0021-8.

PMID:
30154473
12.

A Survey on the Medical Use of Cannabis in Europe: A Position Paper.

Bramness JG, Dom G, Gual A, Mann K, Wurst FM.

Eur Addict Res. 2018;24(4):201-205. doi: 10.1159/000492757. Epub 2018 Aug 22.

PMID:
30134238
13.

Alcoholic liver disease.

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.

Nat Rev Dis Primers. 2018 Aug 16;4(1):16. doi: 10.1038/s41572-018-0014-7. Review. Erratum in: Nat Rev Dis Primers. 2018 Aug 28;4(1):18.

PMID:
30115921
14.

Quality of life role in risky alcohol use research: should it be a more relevant outcome in any study?

López-Pelayo H, Oliveras C, Segura L, Colom J, Díaz E, Wallace P, Gual A.

Adicciones. 2018 Jul 13;30(4):301-303. doi: 10.20882/adicciones.1098. English, Spanish.

15.

Role of Alcohol and Drug Detection by Regular Urine Sample Testing in pre-transplant evaluation for Alcohol Liver Disease.

López Pelayo H, Altamirano J, López E, Barrio P, López A, Gual A, Lligoña A.

Adicciones. 2018 Jul 20;0(0):1121. doi: 10.20882/adicciones.1121. [Epub ahead of print] English, Spanish.

16.

A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?

Barrio Giménez P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.

Adicciones. 2018 Jul 13;0(0):1046. doi: 10.20882/adicciones.1046. [Epub ahead of print] English, Spanish.

17.

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level.

van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon N, Söderpalm B, Sommer WH, Walter H, Spanagel R.

Addict Biol. 2018 Jul;23(4):969-986. doi: 10.1111/adb.12645.

PMID:
30043457
18.

Quantitative Criteria to Screen for Cannabis Use Disorder.

Casajuana C, López-Pelayo H, Miquel L, Balcells-Oliveró MM, Colom J, Gual A.

Eur Addict Res. 2018;24(3):109-117. doi: 10.1159/000488346. Epub 2018 Jun 27.

PMID:
29949807
19.

Optimizing the delivery of interventions for harmful alcohol use in primary healthcare: an update.

Segura L, Anderson P, Gual A.

Curr Opin Psychiatry. 2018 Jul;31(4):324-332. doi: 10.1097/YCO.0000000000000435.

PMID:
29846264
20.

Reducing the health risks derived from exposure to addictive substances.

Anderson P, Gual A, Rehm J.

Curr Opin Psychiatry. 2018 Jul;31(4):333-341. doi: 10.1097/YCO.0000000000000432.

PMID:
29746421

Supplemental Content

Loading ...
Support Center